Skip to content
Screener

Tango Therapeutics TNGX Q2 2025 earnings

Reported August 5, 2025 · Before market open

Revenue$3.2MMiss by $3.2M
EPS-$0.35In line
Revenue estimate$6.4M
EPS estimate-$0.35

Next report

Nov 3, 2026 (in a month)
Revenue estimate$3.3M
EPS estimate-$0.34

Financials

Q2 2025

Income statement

See full
Revenue$3.2M-84.0%
Operating income-$41.0M-38.6%
Net income-$38.9M-52.1%
EPS (diluted)-$0.35-45.8%

Balance sheet

See full
Cash & equivalents$41.8M-22.7%
Total debt$35.0M-7.5%
Total equity$135.0M-45.5%
Total assets$237.9M-37.6%

Cash flow

See full
Operating cash flow-$36.5M-54.7%
CapEx$624.0K+95.0%
Free cash flow-$37.1M-55.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$580.99M-37.4%
Enterprise value$574.16M-37.0%
P/S23.9×+2.1×

Profitability

See full
Operating margin-647.3%-8,982pp
Net margin-599.1%-3,816pp
FCF margin-613.9%-4,451pp

Returns & leverage

See full
Return on equity-76.1%+77.4pp
Debt / equity0.3×+0.1×
Current ratio4.7×-2.7×

FAQ

When did Tango Therapeutics report Q2 2025 earnings?
Tango Therapeutics (TNGX) reported Q2 2025 earnings on August 5, 2025 before market open.
What were Tango Therapeutics's Q2 2025 revenue and EPS?
Tango Therapeutics reported revenue of $3.2M and eps of $-0.35 for Q2 2025.
Did Tango Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $6.4M by $3.2M. EPS beat the consensus estimate of $-0.35 by $0.00.
How did Tango Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 84.0% from $19.9M a year earlier and eps declined 45.8% from $-0.24.
Where can I find Tango Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-102387) and the 10-Q periodic report (0000950170-25-102392) directly on SEC EDGAR. The filing index links above go to sec.gov.